We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Tessera Therapeutics Stock

Invest in or calculate the value of your shares in Tessera Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

Tessera Therapeutics Stock (TETH)

Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.

About Tessera Therapeutics Stock

Founded

2018

Headquarters

Cambridge, MA, US

Industries

Software, Artificial Intelligence, Data and Analytics

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Investors in Tessera Therapeutics

Discover investors in Tessera Therapeutics stock and explore their portfolio companies

Tessera Therapeutics Management

Leadership team at Tessera Therapeutics

Co-Founder & Chief Scientific Officer

Jacob Rubens

President and CFO

Howard Liang

Locked Features

Join now and verify your accreditation status to gain access to:

  • Tessera Therapeutics current valuation
  • Tessera Therapeutics stock price
  • Available deals in Tessera Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Tessera Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like Tessera Therapeutics through EquityZen funds. These investments are made available by existing Tessera Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Tessera Therapeutics stock?

Shareholders can sell their Tessera Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."